mdc-TJK (Olanzapine LAI)
Schizophrenia
Phase 3Active
Key Facts
About MedinCell
MedinCell is a clinical-stage biotech company with a commercial-stage product, specializing in long-acting injectable drug delivery via its proprietary BEPO® technology. The company has successfully partnered with major pharmaceutical firms like Teva, leading to the FDA-approved schizophrenia treatment UZEDY® and a late-stage pipeline including a promising olanzapine LAI. With a recent ~€48 million private placement and a growing revenue stream from its partnered product, MedinCell is positioned to expand its impact in psychiatry and other therapeutic areas while advancing its internal pipeline.
View full company profileTherapeutic Areas
Other Schizophrenia Drugs
| Drug | Company | Phase |
|---|---|---|
| DB103 (Pomaglumetad) | Denovo Biopharma | Phase 2b/3 |
| ZZ6398 | Zhongze Therapeutics | Phase 1/2 |
| RBP-7000 (PERSERIS®) | Indivior | Marketed |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| Schizophrenia Candidate | Teva | Phase 3 |
| Schizophrenia Model Service | NeuroProof | Pre-clinical |
| LYN-005 (Nortiva) | Lyndra | Phase 3 |
| TerXT | Terran Biosciences | Late-stage (Pre-Phase 3) |
| Undisclosed Program | Curemark | Preclinical |
| Schizophrenia Intermediate | OFD Biopharma | Proof of concept |
| Schizophrenia | Keltic Pharma Therapeutics | Pre-clinical |
| AVAT-031 | Avata Biosciences | Discovery |